WO2008022006A3 - Arylalkoxyl hepatitis c virus protease inhibitors - Google Patents

Arylalkoxyl hepatitis c virus protease inhibitors Download PDF

Info

Publication number
WO2008022006A3
WO2008022006A3 PCT/US2007/075653 US2007075653W WO2008022006A3 WO 2008022006 A3 WO2008022006 A3 WO 2008022006A3 US 2007075653 W US2007075653 W US 2007075653W WO 2008022006 A3 WO2008022006 A3 WO 2008022006A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
present
subject
virus
arylalkoxyl
Prior art date
Application number
PCT/US2007/075653
Other languages
French (fr)
Other versions
WO2008022006A2 (en
Inventor
Deqiang Niu
Yonghua Gai
Yat Sun Or
Zhe Wang
Original Assignee
Enanta Pharm Inc
Deqiang Niu
Yonghua Gai
Yat Sun Or
Zhe Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/836,288 external-priority patent/US7687459B2/en
Application filed by Enanta Pharm Inc, Deqiang Niu, Yonghua Gai, Yat Sun Or, Zhe Wang filed Critical Enanta Pharm Inc
Publication of WO2008022006A2 publication Critical patent/WO2008022006A2/en
Publication of WO2008022006A3 publication Critical patent/WO2008022006A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
PCT/US2007/075653 2006-08-11 2007-08-10 Arylalkoxyl hepatitis c virus protease inhibitors WO2008022006A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50341306A 2006-08-11 2006-08-11
US11/503,413 2006-08-11
US11/836,288 US7687459B2 (en) 2006-08-11 2007-08-09 Arylalkoxyl hepatitis C virus protease inhibitors

Publications (2)

Publication Number Publication Date
WO2008022006A2 WO2008022006A2 (en) 2008-02-21
WO2008022006A3 true WO2008022006A3 (en) 2008-10-30

Family

ID=39082988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075653 WO2008022006A2 (en) 2006-08-11 2007-08-10 Arylalkoxyl hepatitis c virus protease inhibitors

Country Status (1)

Country Link
WO (1) WO2008022006A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2624333A1 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
KR20090024834A (en) 2006-07-05 2009-03-09 인터뮨, 인크. Novel inhibitors of hepatitis c virus replication
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
CN101580535B (en) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 Hcv protease inhibitors
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
CA2761650C (en) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN102020698B (en) * 2009-09-15 2012-08-29 太景生物科技股份有限公司 Hepatitis c virus protease inhibitor
DK2477980T3 (en) * 2009-09-15 2016-09-12 Taigen Biotechnology Co Ltd HCV protease inhibitors
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EA201390988A1 (en) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. PHENANTRIDINE MACROCYCLIC INHIBITORS OF THE HYPATITIS C VIRUS SERIN PROTEASE
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012013111U1 (en) 2011-10-21 2015-01-14 Abbvie Inc. A combination of at least two direct-acting antiviral agents for use in the treatment of HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (en) 2011-10-21 2014-05-07 Abbvie Inc DAA combination therapy (eg with ABT-072 or ABT-333) for use in the treatment of HCV
CN104918941A (en) 2012-10-19 2015-09-16 百时美施贵宝公司 Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009543A2 (en) * 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009543A2 (en) * 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9527885B2 (en) 2011-05-05 2016-12-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
WO2008022006A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008021733A3 (en) Tetrazolyl acyclic hepatitis c serine protease inhibitors
MX2010005262A (en) Quinoxaline-containing compounds as hepatitis c virus inhibitors.
MX2010006209A (en) Quinoxalinyl derivatives.
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
MX2010005261A (en) Macrocyclic tetrazolyl hepatitis c serine protease inhibitors.
MX2010006518A (en) Macrocyclic oximyl hepatitis c serine protease inhibitors.
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
MX2010010276A (en) Fluorinated macrocyclic compounds as hepatitis c virus inhibitors.
WO2011049908A3 (en) Bismacrokyclic compounds as hepatitis c virus inhibitors
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
MX2011012155A (en) Macrocyclic compounds as hepatitis c virus inhibitors.
WO2004093798A3 (en) Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
MX2019013037A (en) Macrocyclic proline derived hcv serine protease inhibitors.
WO2009085978A8 (en) Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07800078

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07800078

Country of ref document: EP

Kind code of ref document: A2